Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? - sprookjes - yvandenbroek - TriplyDB

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

http://www.wikidata.org/entity/Q38033521

about

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis Overview of lupus nephritis management guidelines and perspective from Asia.Overview of lupus nephritis management guidelines and perspective from Asia.Treatment of lupus nephritis: practical issues in Asian countries.Treatment of severe lupus nephritis: the new horizon.Lupus nephritis management guidelines compared.Mycophenolate mofetil for lupus nephritis: an update.Towards new avenues in the management of lupus glomerulonephritis.Current and Emerging Therapies for Lupus Nephritis.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.Moderator's view: Cyclophosphamide in lupus nephritis.Clinicopathological and outcome analysis of adult lupus nephritis patients in China.New perspectives and insights to Asian systemic lupus erythematosus: renal disease, genetic predisposition and disease activity.Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study.Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study.Lupus nephritis: Mesenchymal stromal cells in lupus nephritis

P2860

Q33628340-18241327-8BD1-4D99-AF7F-35CF558882E9 Q35544692-A5259383-CD08-491B-97AF-D42B00A2BD15 Q36681801-4E384EFE-7448-4289-BB16-03304A4FF88E Q38123242-ECEA2FA3-E3F8-49F0-AF1C-D140CB5B1850 Q38175076-C5B53EE2-0608-412E-A6C0-389CAB5F1C63 Q38223302-2A35811E-2083-4F47-A9EC-B025129E9927 Q38271125-52E3F84A-A5CD-4C9D-B4DB-DCAC4D43EE0E Q38446941-BF33A58C-205E-4FA4-8B02-D8D6F9FF5AEA Q38585887-763393F0-088A-4366-8950-286873F241BF Q38686467-15A55F9C-64B1-4761-ACD0-73185394AA31 Q38855495-7F29B047-963E-42A6-8A8F-A86A3478F017 Q39218839-EE7678B5-7726-433E-9FDF-551B0B6E4DE1 Q39425964-1B599C74-3026-48E2-967F-7C4D0166D9FD Q39758033-E868F39F-8CCA-47CE-B7B2-967DE46523CB Q41560786-5A7E4540-7E77-4EEC-9EA3-A433514A2E26 Q43626306-1281E8D4-0F5C-41BF-8A0B-58D4EB61A824 Q46119727-959529AB-7F03-4F21-A2AA-B388D5E7DEDC Q53311588-6F12AB91-5FFA-40AD-924F-BFF97AFC9787 Q57789385-45E60DF8-8A94-437A-AB6A-E60DC558BFF8

P2860

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

http://www.wikidata.org/entity/Q38033521

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Lupus nephritis: induction the ...... considered the drug of choice?

@en

type

label

Lupus nephritis: induction the ...... considered the drug of choice?

@en

prefLabel

Lupus nephritis: induction the ...... considered the drug of choice?

@en

P1433

Q38033521-41E59A69-2E0B-4E23-B907-B9D30827BA84

P1476

Q38033521-63269F1C-4D36-4211-82F5-94D37090C408

P2093

Q38033521-3D1A9558-7292-412A-A58D-655C961AAD92

Q38033521-635F8773-1C4C-46D3-ADE1-3608AD466781

Q38033521-697C6655-EE8D-43AA-86EB-66F8AD03D7ED

Q38033521-707B48EB-AE24-47F5-BC18-058EC3499FF9

Q38033521-9BB33975-8C11-46C9-AE86-F864FC9398C3

Q38033521-A760CC86-5C8E-46C3-B7F8-6BA0564AF64E

Q38033521-E0ADAC63-D061-41E0-9BB5-2118A3F95002

Q38033521-E8F9F731-DCCD-4114-A833-2565FB4DFCF4

Q38033521-F07A2064-E942-4D7B-A075-59AB3CE921A3

P304

Q38033521-9A6526FB-E156-4C0F-ACF7-58FC13D11E9C

P31

Q38033521-0FBC9438-765F-46E4-B11E-A8E1DDECD4EB

P356

Q38033521-145C69BA-4305-4420-A1C5-32D3474C9A19

P433

Q38033521-7D3A038D-990E-4766-86CD-4354CCC14F7C

P478

Q38033521-0EA5E56E-AE8A-463F-89F6-4D1DDEEE4B27

P50

Q38033521-7F525FD7-C808-4B14-AB4F-8315F16C67DF

P577

Q38033521-865259D0-66BD-46B9-84DC-EDEA428C81C5

P698

Q38033521-4A0D766D-495D-45CA-8BC1-A2A5700FF045

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Lupus nephritis: induction the ...... considered the drug of choice?

@en

P2093

Brad H Rovin

http://www.w3.org/2001/XMLSchema#string

Chi Chiu Mok

http://www.w3.org/2001/XMLSchema#string

Ellen M Ginzler

http://www.w3.org/2001/XMLSchema#string

Lai Seong Hooi

http://www.w3.org/2001/XMLSchema#string

Lee A Hebert

http://www.w3.org/2001/XMLSchema#string

Neil Solomons

http://www.w3.org/2001/XMLSchema#string

Paul Brunetta

http://www.w3.org/2001/XMLSchema#string

Romeo Maciuca

http://www.w3.org/2001/XMLSchema#string

Samir V Parikh

http://www.w3.org/2001/XMLSchema#string

P304

147-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03290412

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22879439

http://www.w3.org/2001/XMLSchema#string